Alembic Pharmaceuticals Limited drugs

42 results

  • Asenapine (asenapine)

    (Asenapine)
    Alembic Pharmaceuticals Limited
    Usage: Asenapine is indicated for Bipolar I disorder, including acute monotherapy of manic or mixed episodes in pediatric patients aged 10 to 17 years, and as adjunctive treatment with lithium or valproate in adults.

  • Azithromycin (azithromycin)

    (Azithromycin)
    Alembic Pharmaceuticals Limited
    Usage: Azithromycin is indicated for treating mild to moderate infections caused by susceptible bacteria, including acute bacterial exacerbations of chronic bronchitis, sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, skin infections, urethritis, cervicitis, and genital ulcer disease in men. Pediatric uses include acute otitis media and pneumonia in older children.

  • Azithromycin (azithromycin)

    (AZITHROMYCIN)
    Alembic Pharmaceuticals Limited
    Usage: Azithromycin is a macrolide antibacterial indicated for treating mild to moderate infections from susceptible microorganisms. It is also used for prophylaxis and treatment of disseminated Mycobacterium avium complex disease in individuals with advanced HIV infection. Usage should aim to reduce drug resistance in bacteria.

  • Carbidopa and levodopa (carbidopa and levodopa)

    (Carbidopa and Levodopa)
    Alembic Pharmaceuticals Limited
    Usage: Carbidopa and levodopa extended-release tablets are indicated for treating Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.

  • Celecoxib (celecoxib)

    (Celecoxib)
    Alembic Pharmaceuticals Limited
    Usage: Celecoxib is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (ages 2 and older), ankylosing spondylitis, acute pain in adults, and primary dysmenorrhea. Use the lowest effective dose for the shortest duration to achieve treatment goals.

  • Chlordiazepoxide hydrochloride and clidinium bromide (chlordiazepoxide hydrochloride and clidinium bromide)

    (Chlordiazepoxide hydrochloride and clidinium bromide)
    Alembic Pharmaceuticals Limited
    Usage: Chlordiazepoxide hydrochloride and clidinium bromide capsules are indicated for managing emotional and physical symptoms of gastrointestinal disorders, and may serve as adjunctive treatment for peptic ulcers and irritable bowel syndrome (IBS) as well as acute enterocolitis.

  • Chlorpromazine (chlorpromazine)

    (Chlorpromazine)
    Alembic Pharmaceuticals Limited
    Usage: This drug is indicated for managing symptoms of psychotic disorders, treating schizophrenia, controlling nausea and vomiting, relieving pre-surgical restlessness, managing acute intermittent porphyria, assisting in tetanus treatment, addressing manic-depressive illness, controlling intractable hiccups, and treating severe behavioral issues in children aged 1 to 12.

  • Clarithromycin (clarithromycin)

    (Clarithromycin)
    Alembic Pharmaceuticals Limited
    Usage: Clarithromycin tablets are indicated for treating mild to moderate infections in adults and pediatric patients, including acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin infections, acute otitis media, mycobacterial infections in HIV, and H. pylori infections.

  • Clindamycin phosphate (clindamycin phosphate)

    (CLINDAMYCIN PHOSPHATE)
    Alembic Pharmaceuticals Limited
    Usage: Clindamycin phosphate gel is indicated for the treatment of acne vulgaris. Physicians should evaluate the risk of gastrointestinal side effects, including diarrhea, and consider alternative treatments if necessary.

  • Clobetasol propionate (clobetasol propionate)

    (CLOBETASOL PROPIONATE)
    Alembic Pharmaceuticals Limited
    Usage: Clobetasol propionate cream is indicated for relieving inflammatory and pruritic symptoms of corticosteroid-responsive skin conditions. Use is limited to 2 weeks and should not exceed 50 g/week to avoid HPA axis suppression. Not recommended for children under 12; reevaluate if no improvement occurs within 2 weeks.